Q3 2025 EPS Estimates for Editas Medicine, Inc. (NASDAQ:EDIT) Raised by Analyst

Editas Medicine, Inc. (NASDAQ:EDIT) – Analysts at Zacks Research boosted their Q3 2025 earnings estimates for shares of Editas Medicine in a research report issued on Wednesday, April 24th. Zacks Research analyst A. Chakraborty now anticipates that the company will post earnings per share of ($0.74) for the quarter, up from their prior estimate of ($0.75). The consensus estimate for Editas Medicine’s current full-year earnings is ($2.61) per share. Zacks Research also issued estimates for Editas Medicine’s Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($3.04) EPS, Q1 2026 earnings at ($0.67) EPS and FY2026 earnings at ($2.53) EPS.

Several other brokerages have also recently issued reports on EDIT. JPMorgan Chase & Co. lifted their target price on shares of Editas Medicine from $8.00 to $9.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 27th. Citigroup lifted their target price on shares of Editas Medicine from $11.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. Barclays lifted their target price on shares of Editas Medicine from $10.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 29th. Finally, StockNews.com upgraded Editas Medicine from a “sell” rating to a “hold” rating in a report on Friday, March 1st. Five investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Editas Medicine Stock Up 1.9 %

Shares of EDIT opened at $5.32 on Friday. Editas Medicine has a 52-week low of $5.11 and a 52-week high of $11.91. The firm’s fifty day moving average is $7.52 and its two-hundred day moving average is $8.31. The stock has a market cap of $437.52 million, a PE ratio of -2.60 and a beta of 2.01.

Editas Medicine (NASDAQ:EDIT) last announced its earnings results on Wednesday, February 28th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.29. Editas Medicine had a negative net margin of 196.12% and a negative return on equity of 42.95%. The company had revenue of $60.00 million for the quarter, compared to analysts’ expectations of $4.84 million. During the same quarter in the previous year, the company posted ($0.88) EPS. The firm’s quarterly revenue was up 817.4% on a year-over-year basis.

Institutional Trading of Editas Medicine

Several institutional investors and hedge funds have recently bought and sold shares of EDIT. Clear Street Markets LLC acquired a new position in Editas Medicine in the 3rd quarter valued at about $44,000. Russell Investments Group Ltd. grew its position in Editas Medicine by 401.9% in the 4th quarter. Russell Investments Group Ltd. now owns 5,190 shares of the company’s stock valued at $53,000 after acquiring an additional 4,156 shares in the last quarter. Amalgamated Bank grew its position in Editas Medicine by 18.0% in the 3rd quarter. Amalgamated Bank now owns 8,023 shares of the company’s stock valued at $63,000 after acquiring an additional 1,226 shares in the last quarter. Independent Advisor Alliance acquired a new position in Editas Medicine in the 3rd quarter valued at about $81,000. Finally, China Universal Asset Management Co. Ltd. grew its position in Editas Medicine by 351.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,450 shares of the company’s stock valued at $96,000 after acquiring an additional 7,355 shares in the last quarter. 71.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Editas Medicine

In related news, CEO Gilmore Neil O’neill sold 77,824 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $9.42, for a total value of $733,102.08. Following the sale, the chief executive officer now directly owns 327,470 shares in the company, valued at approximately $3,084,767.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Gilmore Neil O’neill sold 77,824 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $9.42, for a total value of $733,102.08. Following the sale, the chief executive officer now directly owns 327,470 shares in the company, valued at approximately $3,084,767.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Baisong Mei sold 20,327 shares of the business’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $9.42, for a total transaction of $191,480.34. Following the completion of the sale, the senior vice president now owns 141,543 shares in the company, valued at $1,333,335.06. The disclosure for this sale can be found here. Insiders own 1.90% of the company’s stock.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.